Characterization of the Specificity, Functionality, and Durability of Host T-Cell Responses Against the Full-Length Hepatitis E Virus

Hepatology

Volumn 64, Issue 6, 2016, Pages 1934-1950

  Brown, Anthony ^a   Halliday, John S ^a,b   Swadling, Leo ^a   Madden, Richie G ^c   Bendall, Richard ^c   Hunter, Jeremy G ^c   Maggs, James ^d   Simmonds, Peter ^a,e   Smith, Donald B ^e   Vine, Louisa ^c   McLaughlin, Cara ^c   Collier, Jane ^d   Bonsall, David ^a   Jeffery, Katie ^d   Dunachie, Susanna ^a   Klenerman, Paul ^a,d,f   Izopet, Jacques ^g   Kamar, Nassim ^g   Dalton, Harry R ^c   Barnes, Eleanor ^a,d,f  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c ROYAL CORNWALL HOSPITAL   (United Kingdom)

^d OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UK Health Security Agency   (United Kingdom)

^g CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; T LYMPHOCYTE RECEPTOR;

ACUTE DISEASE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GENOTYPE; GRAFT RECIPIENT; HEPATITIS E; HEPATITIS E VIRUS; HOST; HUMAN; MALE; NONHUMAN; OPEN READING FRAME; ORGAN TRANSPLANTATION; PEPTIDE LIBRARY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; TIME FACTOR; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; INTERFERON-GAMMA; MALE; MIDDLE AGED; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES; TIME FACTORS; YOUNG ADULT;

EID: 84995666082     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28819     Document Type: Article

References (63)

1. Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology 2012;55:988–997.
2. Mansuy JM, Bendall R, Legrand-Abravanel F, Saune K, Miedouge M, Ellis V, et al. Hepatitis E virus antibodies in blood donors, France. Emerg Infect Dis 2011;17:2309–2312.
3. Dalton HR, Bendall R, Ijaz S, Banks M. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis 2008;8:698–709.
4. Khuroo MS. Discovery of hepatitis E: the epidemic non-A, non-B hepatitis 30 years down the memory lane. Virus Res 2011;161:3–14.
5. Smith DB, Ijaz S, Tedder RS, Hogema B, Zaaijer HL, Izopet J, et al. Variability and pathogenicity of hepatitis E virus genotype 3 variants. J Gen Virol 2015;96:3255–3264.
6. Tam AW, Smith MM, Guerra ME, Huang CC, Bradley DW, Fry KE, et al. Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology 1991;185:120–131.
7. Korkaya H, Jameel S, Gupta D, Tyagi S, Kumar R, Zafrullah M, et al. The ORF3 protein of hepatitis E virus binds to Src homology 3 domains and activates MAPK. J Biol Chem 2001;276:42389–42400.
8. Worm HC, van der Poel WH, Brandstätter G. Hepatitis E: an overview. Microbes Infect 2002;4:657–666.
9. Ropp SL, Tam AW, Beames B, Purdy M, Frey TK. Expression of the hepatitis E virus ORF1. Arch Virol 2000;145:1321–1337.
10. Khuroo MS & Khuroo MS. Hepatitis E: an emerging global disease—from discovery towards control and cure. J Viral Hepat 2016;23:68–79.
11. Khuroo MS, Teli MR, Skidmore S, Sofi MA, Khuroo MI. Incidence and severity of viral hepatitis in pregnancy. Am J Med 1981;70:252–255.
12. Khuroo MS, Kamili S. Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy. J Viral Hepat 2003;10:61–69.
13. Pal R, Aggarwal R, Naik SR, Das V, Das S, Naik S. Immunological alterations in pregnant women with acute hepatitis E. J Gastroenterol Hepatol 2005;20:1094–1101.
14. Nijskens CM, Pas SD, Cornelissen J, Caliskan K, Hoek RA, Hesselink DA, et al. Hepatitis E virus genotype 3 infection in a tertiary referral center in the Netherlands: clinical relevance and impact on patient morbidity. J Clin Virol 2016;74:82–87.
15. Cheng SH, Mai L, Zhu FQ, Pan XF, Sun HX, Cao H, et al. Influence of chronic HBV infection on superimposed acute hepatitis E. World J Gastroenterol 2013;19:5904–5909.
16. Kumar M, Sharma BC, Sarin SK. Hepatitis E virus as an etiology of acute exacerbation of previously unrecognized asymptomatic patients with hepatitis B virus-related chronic liver disease. J Gastroenterol Hepatol 2008;23:883–887.
17. Peron JM, Dalton H, Izopet J, Kamar N. Acute autochthonous hepatitis E in western patients with underlying chronic liver disease: a role for ribavirin? J Hepatol 2011;54:1323–1324; author reply, 1324-1325.
18. Kamar N, Selves J, Mansuy JM, Ouezzani L, Peron JM, Guitard J, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008;358:811–817.
19. Haagsma EB, van den Berg AP, Porte RJ, Benne CA, Vennema H, Reimerink JH, et al. Chronic hepatitis E virus infection in liver transplant recipients. Liver Transpl 2008;14:547–553.
20. Gerolami R, Moal V, Picard C, Colson P. Hepatitis E virus as an emerging cause of chronic liver disease in organ transplant recipients. J Hepatol 2009;50:622–624.
21. Pischke S, Ho H, Urbanek F, Meyer-Olsen D, Suneetha PV, Manns MP, et al. Hepatitis E in HIV-positive patients in a low-endemic country. J Viral Hepat 2010;17:598–599.
22. Colson P, Dhiver C, Poizot-Martin I, Tamalet C, Gerolami R. Acute and chronic hepatitis E in patients infected with human immunodeficiency virus. J Viral Hepat 2011;18:227–228.
23. Ollier L, Tieulie N, Sanderson F, Heudier P, Giordanengo V, Fuzibet JG, et al. Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab. Ann Intern Med 2009;150:430–431.
24. Suneetha PV, Pischke S, Schlaphoff V, Grabowski J, Fytili P, Gronert A, et al. Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. Hepatology 2012;55:695–708.
25. Pischke S, Suneetha PV, Baechlein C, Barg-Hock H, Heim A, Kamar N, et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl 2010;16:74–82.
26. Zhang J, Zhang X-F, Huang S-J, Wu T, Hu Y-M, Wang Z-Z, et al. Long-term efficacy of a hepatitis E vaccine. N Engl J Med 2015;372:914–922.
27. Seriwatana J, Shrestha MP, Scott RM, Tsarev SA, Vaughn DW, Myint KS, et al. Clinical and epidemiological relevance of quantitating hepatitis E virus-specific immunoglobulin M. Clin Diagn Lab Immunol 2002;9:1072–1078.
28. Baylis SA, Crossan C, Corman VM, Blumel J, Scobie L, Dalton HR. Unusual serological response to hepatitis E virus in plasma donors consistent with re-infection. Vox Sang 2015;109:406–409.
29. Favorov MO, Fields HA, Purdy MA, Yashina TL, Aleksandrov AG, Alter MJ, et al. Serologic identification of hepatitis E virus infections in epidemic and endemic settings. J Med Virol 1992;36:246–250.
30. Khudyakov YE, Lopareva EN, Jue DL, Crews TK, Thyagarajan SP, Fields HA. Antigenic domains of the open reading frame 2-encoded protein of hepatitis E virus. J Clin Microbiol 1999;37:2863–2871.
31. Khudyakov YE, Khudyakova NS, Fields HA, Jue D, Starling C, Favorov MO, et al. Epitope mapping in proteins of hepatitis E virus. Virology 1993;194:89–96.
32. Riddell MA, Li F, Anderson DA. Identification of immunodominant and conformational epitopes in the capsid protein of hepatitis E virus by using monoclonal antibodies. J Virol 2000;74:8011–8017.
33. Dawson GJ, Chau KH, Cabal CM, Yarbough PO, Reyes GR, Mushahwar IK. Solid-phase enzyme-linked immunosorbent assay for hepatitis E virus IgG and IgM antibodies utilizing recombinant antigens and synthetic peptides. J Virol Methods 1992;38:175–186.
34. Coursaget P, Buisson Y, Depril N, le Cann P, Chabaud M, Molinie C, et al. Mapping of linear B cell epitopes on open reading frames 2- and 3-encoded proteins of hepatitis E virus using synthetic peptides. FEMS Microbiol Lett 1993;109:251–255.
35. Aggarwal R, Shukla R, Jameel S, Agrawal S, Puri P, Gupta VK, et al. T-cell epitope mapping of ORF2 and ORF3 proteins of human hepatitis E virus. J Viral Hepat 2007;14:283–292.
36. Srivastava R, Aggarwal R, Jameel S, Puri P, Gupta VK, Ramesh VS, et al. Cellular immune responses in acute hepatitis E virus infection to the viral open reading frame 2 protein. Viral Immunol 2007;20:56–65.
37. Srivastava R, Aggarwal R, Sachdeva S, Alam MI, Jameel S, Naik S. Adaptive immune responses during acute uncomplicated and fulminant hepatitis E. J Gastroenterol Hepatol 2011;26:306–311.
38. Tripathy AS, Das R, Rathod SB, Arankalle VA. Cytokine profiles, CTL response and T cell frequencies in the peripheral blood of acute patients and individuals recovered from hepatitis E infection. PLoS One 2012;7:e31822.
39. Pischke S, Gisa A, Suneetha PV, Wiegand SB, Taubert R, Schlue J, et al. Increased HEV seroprevalence in patients with autoimmune hepatitis. PLoS One 2014;9:e85330.
40. van den Berg B, van der Eijk AA, Pas SD, Hunter JG, Madden RG, Tio-Gillen AP, et al. Guillain-Barre syndrome associated with preceding hepatitis E virus infection. Neurology 2014;82:491–497.
41. Baylis SA, Hanschmann KM, Blumel J, Nubling CM. Standardization of hepatitis E virus (HEV) nucleic acid amplification technique-based assays: an initial study to evaluate a panel of HEV strains and investigate laboratory performance. J Clin Microbiol 2011;49:1234–1239.
42. Bendall R, Ellis V, Ijaz S, Ali R, Dalton H. A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. J Med Virol 2010;82:799–805.
43. Smith DB, Vanek J, Ramalingam S, Johannessen I, Templeton K, Simmonds P. Evolution of the hepatitis E virus hypervariable region. J Gen Virol 2012;93:2408–2418.
44. Bonsall D, Ansari MA, Ip C, Trebes A, Brown A, Klenerman P, et al. ve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogens. F1000Res 2015;4:1062.
45. Legrand-Abravanel F, Mansuy JM, Dubois M, Kamar N, Peron JM, Rostaing L, et al. Hepatitis E virus genotype 3 diversity, France. Emerg Infect Dis 2009;15:110–114.
46. Smith DB, Simmonds P, Izopet J, Oliveira-Filho EF, Ulrich RG, Johne R, et al. Proposed reference sequences for hepatitis E virus subtypes. J Gen Virol 2016;97:537–542.
47. von Delft A, Humphreys IS, Brown A, Pfafferott K, Lucas M, Klenerman P, et al. The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design. Gut 2016;65:112–123.
48. Simmonds P. SSE: a nucleotide and amino acid sequence analysis platform. BMC Res Notes 2012;5:50.
49. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol 2013;30:2725–2729.
50. Li S, Zhang J, Xia N. Lessons from hepatitis E vaccine design. Curr Opin Virol 2015;11:130–136.
51. Li SW, Zhang J, Li YM, Ou SH, Huang GY, He ZQ, et al. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine 2005;23:2893–2901.
52. + T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. J Virol 2006;80:3532–3540.
53. Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol 2014;14:24–35.
54. Fuller MJ, Hildeman DA, Sabbaj S, Gaddis DE, Tebo AE, Shang L, et al. Cutting edge: emergence of CD127high functionally competent memory T cells is compromised by high viral loads and inadequate T cell help. J Immunol 2005;174:5926–5930.
55. Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 2003;4:1191–1198.
56. Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010;376:895–902.
57. Shrestha MP, Scott RM, Joshi DM, Mammen MP, Jr., Thapa GB, Thapa N, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007;356:895–903.
58. Chadha MS, Walimbe AM, Arankalle VA. Retrospective serological analysis of hepatitis E patients: a long-term follow-up study. J Viral Hepat 1999;6:457–461.
59. Li RC, Ge SX, Li YP, Zheng YJ, Nong Y, Guo QS, et al. Seroprevalence of hepatitis E virus infection, rural southern People's Republic of China. Emerg Infect Dis 2006;12:1682–1688.
60. Sood A, Midha V, Sood N. Guillain-Barré syndrome with acute hepatitis E. Am J Gastroenterol 2000;95:3667–3668.
61. Fong F, Illahi M. Neuralgic amyotrophy associated with hepatitis E virus. Clin Neurol Neurosurg 2009;111:193–195.
62. Mandal K, Chopra N. Acute transverse myelitis following hepatitis E virus infection. Indian Pediatr 2006;43:365–366.
63. Fadda L, Borhis G, Ahmed P, Cheent K, Pageon SV, Cazaly A, et al. Peptide antagonism as a mechanism for NK cell activation. Proc Natl Acad Sci U S A 2010;107:10160–10165.